65PDHigh tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4Brandon W. Higgs,Christopher Morehouse,Philip Brohawn,Sriram Sridhar,Rajiv Raja,G Gao,Judson Englert,Koustubh RanadeAnnals of Oncology(2018)引用 5|浏览19暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要